1.Prognostic Value of EGFR Mutation Subtypes After Linac-Based Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy for Brain Metastasis From EGFR-Mutated Non-Small Cell Lung Cancer
Ryosuke MATSUDA ; Shigeto HONTSU ; Tetsuro TAMAMOTO ; Nobuyoshi INOOKA ; Akihiro DOI ; Kaori YAMAKI ; Sachiko MIURA ; Ryosuke MAEOKA ; Tsutomu NAKAZAWA ; Tomoko OCHI ; Toshiteru MIYASAKA ; Yasuhiro TAKESHIMA ; Shuichi YAMADA ; Fumihiko NISHIMURA ; Young-Soo PARK ; Fumiaki ISOHASHI ; Ichiro NAKAGAWA
Brain Tumor Research and Treatment 2026;14(2):66-73
Background:
This study aimed to evaluate the differences in common types of epidermal growthfactor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) with brain metastasis (BM) treated using linear accelerator-based stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (fSRT).
Methods:
Between January 2011–December 2023, among 294 consecutive patients with BMfrom NSCLC, 84 patients with EGFR-mutated NSCLC were enrolled in this study.
Results:
The median follow-up time after SRS/fSRT was 20.1 months (range: 0.6–109.7months), while the median overall survival (mOS) after SRS/fSRT was 25.1 months (95% confidence interval [CI]: 18.4–33.5 months). The mOS after initial treatment for NSCLC was 56.2 months (95% CI:41.7–77.0 months). The mOS after SRS/fSRT in 34 patients with exon 19 deletions and 45 patients with exon 21 mutations with L858R was 20.4 months (95% CI: 13.6–55.9 months) and 28.5 months (95% CI: 16.2–33.5). The two groups showed no difference in the mOS. In univariate analyses using the Cox proportional hazards model, no prognostic factors associated with prolonged survival were identified except for good pretreatment Karnofsky Performance Status score and no prior tyrosine kinase inhibitor use before SRS/fSRT in EGFR-mutated NSCLC. There was no difference in both distant failure and local control in the two groups.
Conclusion
The difference in survival between EGFR subtypes (exon 21 L858R mutations vs.exon 19 deletion) was not observed after SRS/fSRT in NSCLC.
2.7-12 Teaching Professionalism and Behavioral Science by Using Online Tools under the COVID-19 Pandemic
Tomoko MIYOSHI ; Masaomi YAMANE ; Yoshinori KOSAKI ; Hitomi KATAOKA ; Yuya YOKOTA ; Eiko MITSUDA ; Kanako OCHI ; Mikako OBIKA ; Hideo INO ; Akihiro MATSUKAWA ; Aiji OHTSUKA
Medical Education 2020;51(3):279-281
3.Laboratory practice in transfusion medicine for medical students and physicians at Okayama University Hospital
Kazuma IKEDA ; Haruko SUGIYAMA ; Tohru IKEDA ; Naomi ASANO ; Hiroaki OGO ; Tomoko MIYOSHI ; Hitomi KATAOKA ; Takaaki MIZUSHIMA ; Yoshio NAKAMURA ; Nobuchika KUSANO ; Hiroki OKADA ; Koji OCHI ; Norio KOIDE
Medical Education 2010;41(1):51-53
1) All students but 1 correctly typed the ABO blood groups, but only 33.2% of students and 63.9% of physicians properly performed cross-matching.
2) Most failures in cross-matching were due to the inability to detect allogeneic antibodies, but 5.2% of students and 2.9% of physicians failed to detect ABO mismatching.
3) Although laboratory practice is suggested to help students to solidify knowledge and comprehend principles, achieving an official goal of residency - gaining competence in performing and interpreting cross-matching independently - appeared difficult.


Result Analysis
Print
Save
E-mail